Search results
Showing 7351 to 7365 of 7702 results
This guidance has been updated and replaced by NICE interventional procedures guidance 570.
Antimicrobial prescribing: nebulised liposomal amikacin (ES36)
This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.
Common mental health problems: identification and pathways to care (CG123)
We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:
Intrapartum care for healthy women and babies - rectal examination after delivery
Discontinued [GID-NG10395]
Violence and aggression: short-term management in mental health, health and community settings
Discontinued [GID-NG10397]
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development [GID-TA11569] Expected publication date: TBC
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued [GID-TA11522]
This guidance has been updated and replaced by NICE interventional procedures guidance 793.
In development [GID-TA11401] Expected publication date: TBC
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)
This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.
This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.
The MAGEC system for spinal lengthening in children with scoliosis (MTG18)
August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.
In development [GID-MT538] Expected publication date: TBC
NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection because there is published evidence that shows it offers no clinical benefits over standard care (clean catch method).
In development [GID-TA11165] Expected publication date: TBC